Atopiclair efficacy — reduces the need for steroid medication in infants and children3
Study design: 139 children aged 6 months to 12 years with mild to moderate flare
symptoms were treated 3 times a day in a randomized, double-blind,
vehicle-controlled study. Children were treated with either Atopiclair or vehicle (cream
base without Atopiclair key ingredients) for 43 days.
• 91% of Atopiclair patients did not need a steroid rescue
medication to
manage flare in a 43-day study, significantly fewer than vehicle (P<.005)
• The most frequently reported adverse events in the Atopiclair-treated
vs
vehicle-treated groups were burning (6.9% vs 7.1%) and stinging
(8.3% vs 2.8%)
Atopiclair efficacy — reduces the need for steroid medication in adults2
Study design: 218 adults with mild to moderate flare symptoms were treated 3 times a day in a randomized, double-blind, vehicle-controlled study. Patients were treated with either Atopiclair or vehicle (cream base without Atopiclair key ingredients) for 50 days.
• Significantly fewer Atopiclair patients than vehicle patients
required a
steroid rescue medication to manage flare (P<.0001) during a 50-day study
• The most frequently reported adverse events in Atopiclair-treated
vs
vehicle-treated groups were common cold (5.5% vs 6.8%) and rash
(2.1% vs 5.5%)
Under the supervision of a health care professional,
Atopiclair nonsteroidal cream is indicated to manage and
relieve the itching, burning and pain experienced with
various types of dermatoses, including atopic dermatitis and
allergic contact dermatitis. Atopiclair nonsteroidal cream
helps to relieve dry, waxy skin by maintaining a moist skin
environment, which is beneficial to the healing process.
Atopiclair nonsteroidal cream does not contain milk, wheat,
peanut or animal derivatives. Atopiclair nonsteroidal cream
does contain shea butter (butyrospermum parkii), a
derivative of shea nut oil (not peanut oil). Patients with a
known allergy to nuts or nut oils should consult their
physician before using this topical preparation.
Frequently reported adverse events in Atopiclair-treated and vehicle-treated groups were burning (6.9% vs 7.1%) and stinging (8.3% vs 2.8%).